The TTBK2 gene plays a crucial role in the development of Spinocerebellar Ataxia Type 11 (SCA11), a condition characterized by progressive coordination problems due to cerebellar ataxia. This condition is inherited in an autosomal dominant manner, meaning only one copy of the altered gene in each cell is sufficient to cause the disorder. As a part of diagnostic measures, genetic testing for mutations in the TTBK2 gene can provide definitive confirmation of SCA11.
At DNA Labs UAE, individuals concerned about their genetic predisposition to SCA11 can undergo a specific genetic test targeting the TTBK2 gene. The cost of this test is set at 4400 AED. This test is crucial for individuals with a family history of SCA11, as it can help in early diagnosis, allowing for timely intervention and management strategies to slow the progression of symptoms. The testing process involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed for mutations in the TTBK2 gene.
The PPP2R2B gene is associated with Spinocerebellar Ataxia Type 12 (SCA12), a rare hereditary disorder characterized by progressive degeneration of the cerebellum, the part of the brain that is responsible for coordinating movement. This condition typically manifests as tremors, unsteady gait, and difficulty with fine motor tasks. SCA12 is an autosomal dominant condition, meaning that an individual only needs a single copy of the altered gene from one parent to be affected.
To diagnose this condition, a genetic test targeting the PPP2R2B gene can be conducted. This test looks for specific mutations in the gene that are known to cause SCA12. Identifying these mutations can confirm a diagnosis, help assess the risk of passing the condition to offspring, and aid in the management and treatment of symptoms.
In the United Arab Emirates, DNA Labs UAE offers this specific genetic test. The cost of the test is 4400 AED. DNA Labs UAE is equipped with state-of-the-art technology to provide accurate and reliable genetic testing services. By opting for this test, individuals who have a family history of SCA12 or exhibit symptoms associated with the condition can gain valuable insights into their genetic makeup, enabling informed decisions regarding their health and future.
The "WWOX Gene Spinocerebellar Ataxia Type 12 Autosomal Recessive Genetic Test" is a specialized diagnostic procedure designed to identify mutations in the WWOX gene, which have been linked to Spinocerebellar Ataxia Type 12 (SCA12), an autosomal recessive neurodegenerative disorder. This condition is characterized by progressive coordination problems, difficulty with speech, and tremors due to cerebellar atrophy. The test aims to provide crucial genetic information for affected individuals and their families, facilitating early diagnosis and management of the condition.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test employs advanced genomic technologies to ensure accurate and reliable results. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis and expertise required to interpret the genetic data accurately. This test is pivotal for at-risk families, offering insights into genetic predispositions and enabling informed decisions regarding health management and potential treatments.
The KCNC3 gene is associated with a condition known as Spinocerebellar Ataxia Type 13 (SCA13), which is a type of hereditary ataxia. SCA13 is characterized by a progressive degeneration of the cerebellum, the part of the brain that is responsible for coordinating movement. This condition leads to symptoms such as uncoordinated movement, poor balance, and difficulty with speech. SCA13 is inherited in an autosomal dominant manner, meaning that an individual only needs a single copy of the altered gene from one parent to be affected.
A genetic test is available to identify mutations in the KCNC3 gene, which can confirm a diagnosis of SCA13. This test is crucial for individuals with a family history of the condition or those exhibiting symptoms, as it can provide a definitive diagnosis and help guide management and treatment options. Additionally, it can offer information for family planning.
In the UAE, this specific genetic test can be conducted at DNA Labs, a facility known for its comprehensive genetic testing services. The cost of the KCNC3 gene test for Spinocerebellar Ataxia Type 13 at DNA Labs UAE is 4400 AED. This test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to detect mutations in the KCNC3 gene. The results of this test can provide individuals and families with essential information regarding the diagnosis, prognosis, and inheritance pattern of SCA13, enabling them to make informed decisions about their health and future.
The GRM1 gene, associated with Spinocerebellar Ataxia Type 13 (SCA13), plays a crucial role in the development and function of the cerebellum, which is responsible for coordinating movement. Mutations in this gene can lead to SCA13, a condition characterized by progressive problems with movement, including poor coordination, unsteady walking, and involuntary eye movements. This condition is inherited in an autosomal recessive pattern, meaning that an individual must receive a mutated gene from both parents to be affected.
In the United Arab Emirates, DNA Labs UAE offers a genetic test specifically designed to identify mutations in the GRM1 gene that cause Spinocerebellar Ataxia Type 13. This test is critical for individuals with a family history of the condition or those exhibiting symptoms, as it can provide a definitive diagnosis. The test involves collecting a DNA sample, usually through a blood draw or cheek swab, and analyzing it for the presence of mutations in the GRM1 gene.
The cost of the GRM1 gene test at DNA Labs UAE is 4400 AED. This test is an important tool for genetic counseling, helping families understand the risk of passing the condition to future generations. It also assists healthcare professionals in managing and treating the condition more effectively, by tailoring interventions to the specific needs of individuals with SCA13.
The PRKCG Gene Spinocerebellar Ataxia Type 14 Autosomal Dominant Genetic Test is a specialized diagnostic procedure designed to identify mutations in the PRKCG gene, which are known to cause Spinocerebellar Ataxia Type 14 (SCA14). SCA14 is a form of spinocerebellar ataxia, a neurodegenerative disorder characterized by progressive problems with movement, coordination, and balance, due to degeneration of the cerebellum and its connections. It is inherited in an autosomal dominant manner, meaning a mutation in just one of the two copies of the gene in each cell is sufficient to cause the disorder.
This test is particularly crucial for individuals with a family history of SCA14, displaying symptoms of the condition, or couples planning to have children and wanting to assess the risk of passing the condition onto their offspring. By analyzing the DNA to detect mutations in the PRKCG gene, this test can confirm a diagnosis of SCA14, assist in the management and treatment of the condition, and provide essential information for genetic counseling.
The test is offered by DNA Labs UAE, a facility known for its state-of-the-art genetic testing services. The cost of the PRKCG Gene Spinocerebellar Ataxia Type 14 Autosomal Dominant Genetic Test is 4400 AED. Given the complexity of the condition and the implications of the test results, individuals are often advised to undergo genetic counseling before and after the test to fully understand the potential outcomes and their impact.
The ITPR1 gene plays a crucial role in the proper functioning of the cerebellum, a part of the brain responsible for coordinating movement. Mutations in this gene can lead to Spinocerebellar Ataxia Type 15 (SCA15), a genetic disorder characterized by progressive deterioration of motor skills, balance issues, and coordination difficulties. The ITPR1 Gene Spinocerebellar Ataxia Type 15 Genetic Test is a specialized diagnostic tool designed to detect mutations in the ITPR1 gene, confirming the diagnosis of SCA15. This test is particularly valuable for individuals showing symptoms of ataxia or those with a family history of the condition, as it can provide definitive genetic evidence of SCA15.
Conducted by DNA Labs UAE, a leading facility in genetic testing, the test offers a comprehensive analysis of the ITPR1 gene. The cost of the test is set at 4400 AED, reflecting the intricate technology and expertise required to accurately identify mutations associated with the condition. By opting for this test, patients and their families can gain crucial insights into their genetic makeup, enabling informed decisions about management and treatment options for Spinocerebellar Ataxia Type 15.
The TBP Gene Spinocerebellar Ataxia Type 17 (SCA17) Autosomal Dominant Genetic Test is a specialized diagnostic procedure aimed at detecting mutations in the TBP gene, which are responsible for causing SCA17. This condition is a form of spinocerebellar ataxia characterized by progressive degeneration of the cerebellum and other regions of the brain, leading to symptoms such as uncoordinated movements, balance problems, and difficulties with speech. The test is crucial for individuals with a family history of SCA17 or those exhibiting symptoms, as it helps in confirming the diagnosis, enabling early intervention and management strategies.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves analyzing the patient's DNA sample, typically obtained from a blood draw, to identify the specific trinucleotide repeat expansion in the TBP gene that causes SCA17. The presence of an abnormal number of repeats confirms the diagnosis of SCA17.
The cost of the TBP Gene Spinocerebellar Ataxia Type 17 Autosomal Dominant Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated nature of the testing process, including the use of advanced genetic sequencing technologies and the expertise required to interpret the results accurately. For individuals at risk, this test provides invaluable information that can guide treatment decisions and genetic counseling, offering insights into the likelihood of passing the condition on to future generations.
The CWF19L1 gene test for Spinocerebellar Ataxia Type 17 (SCA17) is a specialized genetic test designed to detect mutations in the CWF19L1 gene, which have been associated with the development of this particular form of spinocerebellar ataxia. SCA17 is a rare, autosomal recessive neurodegenerative disorder characterized by a combination of cerebellar ataxia, which affects coordination and balance, along with other potential neurological symptoms. This condition is caused by genetic mutations, and identifying these mutations can be crucial for accurate diagnosis, family planning, and understanding the risk of transmission to offspring.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test offers a comprehensive analysis of the CWF19L1 gene to identify mutations that could lead to SCA17. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the expertise required to interpret the results accurately.
Given the autosomal recessive inheritance pattern of the condition tested for, both copies of the gene in an individual must carry the mutation for the person to manifest symptoms of SCA17. This means that carriers, with only one mutated gene, do not typically show symptoms but can pass the mutated gene to their offspring.
Choosing to undergo this test at DNA Labs UAE ensures access to cutting-edge genetic testing technology, along with the support of genetic counselors and specialists who can provide comprehensive advice and interpretation of the test results, guiding patients through the complexities of genetic information and its implications for their health and family planning decisions.
The IFRD1 gene plays a crucial role in the genetic landscape of Spinocerebellar Ataxia Type 18 (SCA18), a rare, autosomal dominant neurological disorder characterized by impaired coordination and balance due to cerebellar degeneration. Individuals with mutations in the IFRD1 gene may exhibit symptoms such as unsteady gait, speech difficulties, and involuntary eye movements, which typically emerge due to the progressive nature of the disease.
To identify the presence of genetic mutations associated with SCA18, DNA Labs UAE offers a specialized genetic test targeting the IFRD1 gene. This test is pivotal for individuals with a family history of SCA18 or those exhibiting symptoms suggestive of the condition, providing a definitive diagnosis and enabling informed decisions regarding management and family planning.
The test is priced at 4400 AED and involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory for mutations in the IFRD1 gene. The process is conducted with utmost confidentiality and accuracy, ensuring reliable results for patients and their families.
